Lundbeck raises 2026 revenue, EBITDA forecasts

Lundbeck reported third-quarter revenue of DKK 6.603 billion, up about 5% year over year, while net earnings rose to DKK 1.267 billion. Adjusted EBITDA reached DKK 2.261 billion, exceeding analyst expectations, and the company said growth was led by migraine drug Vyepti, with Rexulti also contributing. For the first nine months of 2026, revenue increased 13% at constant exchange rates, supported by growth across regions and strategic brands. Lundbeck raised its 2026 outlook, now forecasting revenue growth of 11% to 12% and adjusted EBITDA growth of 15% to 19% at constant exchange rates, up from prior ranges of 7% to 9% and 8% to 14%, respectively. The company attributed the higher outlook mainly to Vyepti’s continued strength in the U.S. and better-than-expected results in partner markets, and expects research and development investment of about DKK 5.6 billion to DKK 5.7 billion.